Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2351 - 2375 of 14960 in total

Infliximab

Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in...
Approved
Matched Description: … composed of human constant (75%) and murine variable (25%) regions [A31469]. ... Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody ... Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Cisplatin

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Approved
Matched Description: … ovarian cancer), lymphomas and germ cell tumors. ... It was the first member of its class, which now also includes carboplatin and oxaliplatin. ... to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …

Quizartinib

Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... thus poorer overall survival and higher risk of relapse. ... anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Demecarium

Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase...
Approved
Matched Description: … Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. ... In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Plasma protein fraction (human)

The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma. It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. This biologic should come...
Approved
Matched Description: … [L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains ... some electrolytes such as sodium, potassium and chloride. ... protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Polygala senega root

Approved
Experimental
Matched Categories: … Cough and Cold Preparations …

Umeclidinium

Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less...
Approved
Matched Description: … fluticasone furoate] under the brand name ANORO ELLIPTA and TRELEGY ELLIPTA respectively. ... progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and ... [A7719] By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and …
Matched Categories: … vilanterol and umeclidinium bromide ... vilanterol, umeclidinium bromide and fluticasone furoate …

Letrozole

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Approved
Investigational
Matched Description: … ], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Nimesulide

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has...
Approved
Investigational
Withdrawn
Matched Description: … primary dysmenorrhoea in adolescents and adults above 12 years old. ... Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and ... Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Fremanezumab

Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. ... [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and ... oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Aurothioglucose

Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s...
Approved
Withdrawn
Matched Description: … use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and ... Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and ... replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and …
Matched Categories: … Antiinflammatory and Antirheumatic Products …

Olive oil

Oil extracted from olives . Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Approved
Matched Description: … Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. ... Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products …
Matched Categories: … Diet, Food, and Nutrition …

Echinacea

Approved
Experimental
Matched Categories: … Herbs and Natural Products …

Saw palmetto

Saw palmetto is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Categories: … Herbs and Natural Products …

Elacestrant

Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.[L44918,L44948] It received a similar approval in the EU in September 2023. Elacestrant binds to estrogen receptor-alpha (ERα)...
Approved
Investigational
Matched Description: … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. ... degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote its ... [L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …

Sorafenib

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also...
Approved
Investigational
Matched Description: … in tumour cell proliferation and tumour angiogenesis. ... Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. ... It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tralokinumab

Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus. It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous...
Approved
Investigational
Matched Description: … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated ... was subsequently approved in Canada in October 2021 and the US in December 2021. ... dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Vonicog alfa

Vonicog alfa is a recombinant von Willebrand factor manufactured by Baxalta. It was FDA approved in December 2015. The gen of von Willebrand factor was first cloned in 1985 by Stuart Orkin and David Ginsburg. By the EMA, vonicog alfa is still under clinical analysis.
Approved
Investigational
Matched Description: … [A32230] The gen of von Willebrand factor was first cloned in 1985 by Stuart Orkin and David Ginsburg …

Zotepine

Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's. Zotepine was never approved by the FDA. In 1993,...
Approved
Investigational
Withdrawn
Matched Description: … [A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany ... It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. ... In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied …

Nirmatrelvir

Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. Without the activity of the SARS-CoV-2 3CLPRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.[A234224,A234229,A234234]...
Approved
Investigational
Matched Description: … [L33354] 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. ... in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and ... granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and …
Matched Categories: … nirmatrelvir and ritonavir ... Amino Acids, Peptides, and Proteins …

Rituximab

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally...
Approved
Matched Description: … sequences and human constant region sequences [A40017], [FDA label]. ... The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region ... chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Canagliflozin

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018...
Approved
Matched Description: … It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 ... inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and canagliflozin …

Omidenepag isopropyl

Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. Omidenepag isopropyl is quickly metabolized to its active metabolite, omidenepag, a molecule with high selectivity and agonistic activity towards the prostaglandin E2 (EP2) receptor.[A253263,A253268] Prostanoid FP receptor agonists (FP...
Approved
Investigational
Matched Description: … topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ... isopropyl is quickly metabolized to its active metabolite, omidenepag, a molecule with high selectivity and ... [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular …

Tipiracil

Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been...
Approved
Investigational
Matched Description: … metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and …

Sulfur hexafluoride

Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric...
Approved
Matched Description: … ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and ... echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and …
Displaying drugs 2351 - 2375 of 14960 in total